New Pharma Drug For Measles Exposure Gets FDA Approval

The US Food and Drug Administration has approved a new drug that’s intended to protect people who have been exposed to measles or hepatitis A. The drug is intended to combat the illnesses in place of vaccinations which “may take weeks to work” after a recent exposure.

Pharmaceutical company Grifols is behind the drug, GamaSTAN®, an immune globulin product that works post-exposure.

“Vaccination, while a valuable option for hepatitis A and measles post-exposure prophylaxis, may take several weeks to take effect as your immune system works to build the antibodies it needs to fight these viruses,” said Stephen Scholand, M.D., infectious disease specialist at MidState Medical Center, said in a statement. “Immune globulins such as GamaSTAN® have been a valuable treatment option for many decades because they offer immediate and rapid protection with antibodies that fight infection.”



by Ole Dammegard

What happened in Iran changed his life. His entire world, his viewpoints and values were turned upside down and the emotional turbulence he experienced tore down his inner walls leaving him naked and vulnerable – like an open wound. After a tragic murder, the situation became unbearale for one of his Iranian friends, so he ventured everything to help him get away and together the mad a dramatic escape from Iran via former Soviet and East Germany in a desperate attempt to reach Sweden. This book is a true and emotional description of real people in improbable world full of conflicts. It opens doors and spreads light on another Iran, its people and also, not least, the political and social conditions in the country. It is permeated by passion and tension as well as human ideals such as non-violence, tolerance and love.

To preview the book click on the thumbnail below:

Buy the paperback here Buy the eBook here

The drug is intended for people over the age of 40 who are exposed to measles or hepatitis A.

“The CDC also recommends that immune globulin should be used for children aged less than 12 months, immunocompromised persons, persons with chronic liver disease and persons who are allergic to the vaccine or a vaccine component. When administered within 2 weeks after exposure to HAV, immune globulin is 80 to 90 percent effective in preventing hepatitis A infection.”

An immune globulin is intended to reduce the severity of the condition.

Of course, health officials still believe older adults should be vigilant with vaccines.

Original Article

Image 1

Image 2

Image 3

Image 4